Selected research
Industry Research
Low Molecular Heparin Preparation Industry Research Report 2026
Market perspective
The global Low Molecular Heparin Preparation market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Low Molecular Heparin Preparation is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Low Molecular Heparin Preparation is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Low Molecular Heparin Preparation is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Low Molecular Heparin Preparation include ALFA WASSERMANN, Aspen (N.V.Organon), Qianhong Bio-pharma, Tiandong, GlaxoSmithKline, Hangzhou Jiuyuan Gene Engineering, Changshan Pharm, Pfizer and Jiangsu Da Lian Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Low Molecular Heparin Preparation market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Low Molecular Heparin Preparation Market by Company
ALFA WASSERMANN
Aspen (N.V.Organon)
Qianhong Bio-pharma
Tiandong
GlaxoSmithKline
Hangzhou Jiuyuan Gene Engineering
Changshan Pharm
Pfizer
Jiangsu Da Lian Pharmaceutical
King-friend Biochemical Pharmaceutical
Xinbai
Qilu Pharmaceutica
Sanofi
Hepalink
Tianjin Chase Sun Pharmaceutical
Dongcheng Biochemicals
Zhaoke Pharmaceutical
Low Molecular Heparin Preparation Segment by Type
Dalteparin Sodium
Nadroparin Calcium
Enoxaparin Sodium
Low Molecular Heparin Preparation Segment by Application
Hospital
Pharmacy
Low Molecular Heparin Preparation Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Low Molecular Heparin Preparation market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Low Molecular Heparin Preparation and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Low Molecular Heparin Preparation.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Low Molecular Heparin Preparation manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Low Molecular Heparin Preparation by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Low Molecular Heparin Preparation in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global Low Molecular Heparin Preparation Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
Table 6. Global Low Molecular Heparin Preparation Sales (W Units) of Manufacturers (2021-2026)
Table 7. Global Low Molecular Heparin Preparation Sales Market Share by Manufacturers (2021-2026)
Table 8. Global Low Molecular Heparin Preparation Revenue of Manufacturers (2021-2026)
Table 9. Global Low Molecular Heparin Preparation Revenue Share by Manufacturers (2021-2026)
Table 10. Global Market Low Molecular Heparin Preparation Average Price (US$/Unit) of Manufacturers (2021-2026)
Table 11. Global Low Molecular Heparin Preparation Industry Ranking, 2024 VS 2025 VS 2026
Table 12. Global Manufacturers of Low Molecular Heparin Preparation, Manufacturing Sites & Headquarters
Table 13. Global Manufacturers of Low Molecular Heparin Preparation, Product Type & Application
Table 14. Global Low Molecular Heparin Preparation Manufacturers Established Date
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Low Molecular Heparin Preparation by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 18. ALFA WASSERMANN Company Information
Table 19. ALFA WASSERMANN Business Overview
Table 20. ALFA WASSERMANN Low Molecular Heparin Preparation Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 21. ALFA WASSERMANN Low Molecular Heparin Preparation Product Portfolio
Table 22. ALFA WASSERMANN Recent Developments
Table 23. Aspen (N.V.Organon) Company Information
Table 24. Aspen (N.V.Organon) Business Overview
Table 25. Aspen (N.V.Organon) Low Molecular Heparin Preparation Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 26. Aspen (N.V.Organon) Low Molecular Heparin Preparation Product Portfolio
Table 27. Aspen (N.V.Organon) Recent Developments
Table 28. Qianhong Bio-pharma Company Information
Table 29. Qianhong Bio-pharma Business Overview
Table 30. Qianhong Bio-pharma Low Molecular Heparin Preparation Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 31. Qianhong Bio-pharma Low Molecular Heparin Preparation Product Portfolio
Table 32. Qianhong Bio-pharma Recent Developments
Table 33. Tiandong Company Information
Table 34. Tiandong Business Overview
Table 35. Tiandong Low Molecular Heparin Preparation Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 36. Tiandong Low Molecular Heparin Preparation Product Portfolio
Table 37. Tiandong Recent Developments
Table 38. GlaxoSmithKline Company Information
Table 39. GlaxoSmithKline Business Overview
Table 40. GlaxoSmithKline Low Molecular Heparin Preparation Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 41. GlaxoSmithKline Low Molecular Heparin Preparation Product Portfolio
Table 42. GlaxoSmithKline Recent Developments
Table 43. Hangzhou Jiuyuan Gene Engineering Company Information
Table 44. Hangzhou Jiuyuan Gene Engineering Business Overview
Table 45. Hangzhou Jiuyuan Gene Engineering Low Molecular Heparin Preparation Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 46. Hangzhou Jiuyuan Gene Engineering Low Molecular Heparin Preparation Product Portfolio
Table 47. Hangzhou Jiuyuan Gene Engineering Recent Developments
Table 48. Changshan Pharm Company Information
Table 49. Changshan Pharm Business Overview
Table 50. Changshan Pharm Low Molecular Heparin Preparation Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 51. Changshan Pharm Low Molecular Heparin Preparation Product Portfolio
Table 52. Changshan Pharm Recent Developments
Table 53. Pfizer Company Information
Table 54. Pfizer Business Overview
Table 55. Pfizer Low Molecular Heparin Preparation Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 56. Pfizer Low Molecular Heparin Preparation Product Portfolio
Table 57. Pfizer Recent Developments
Table 58. Jiangsu Da Lian Pharmaceutical Company Information
Table 59. Jiangsu Da Lian Pharmaceutical Business Overview
Table 60. Jiangsu Da Lian Pharmaceutical Low Molecular Heparin Preparation Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 61. Jiangsu Da Lian Pharmaceutical Low Molecular Heparin Preparation Product Portfolio
Table 62. Jiangsu Da Lian Pharmaceutical Recent Developments
Table 63. King-friend Biochemical Pharmaceutical Company Information
Table 64. King-friend Biochemical Pharmaceutical Business Overview
Table 65. King-friend Biochemical Pharmaceutical Low Molecular Heparin Preparation Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 66. King-friend Biochemical Pharmaceutical Low Molecular Heparin Preparation Product Portfolio
Table 67. King-friend Biochemical Pharmaceutical Recent Developments
Table 68. Xinbai Company Information
Table 69. Xinbai Business Overview
Table 70. Xinbai Low Molecular Heparin Preparation Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 71. Xinbai Low Molecular Heparin Preparation Product Portfolio
Table 72. Xinbai Recent Developments
Table 73. Qilu Pharmaceutica Company Information
Table 74. Qilu Pharmaceutica Business Overview
Table 75. Qilu Pharmaceutica Low Molecular Heparin Preparation Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Qilu Pharmaceutica Low Molecular Heparin Preparation Product Portfolio
Table 77. Qilu Pharmaceutica Recent Developments
Table 78. Sanofi Company Information
Table 79. Sanofi Business Overview
Table 80. Sanofi Low Molecular Heparin Preparation Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Sanofi Low Molecular Heparin Preparation Product Portfolio
Table 82. Sanofi Recent Developments
Table 83. Hepalink Company Information
Table 84. Hepalink Business Overview
Table 85. Hepalink Low Molecular Heparin Preparation Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Hepalink Low Molecular Heparin Preparation Product Portfolio
Table 87. Hepalink Recent Developments
Table 88. Tianjin Chase Sun Pharmaceutical Company Information
Table 89. Tianjin Chase Sun Pharmaceutical Business Overview
Table 90. Tianjin Chase Sun Pharmaceutical Low Molecular Heparin Preparation Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Tianjin Chase Sun Pharmaceutical Low Molecular Heparin Preparation Product Portfolio
Table 92. Tianjin Chase Sun Pharmaceutical Recent Developments
Table 93. Dongcheng Biochemicals Company Information
Table 94. Dongcheng Biochemicals Business Overview
Table 95. Dongcheng Biochemicals Low Molecular Heparin Preparation Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Dongcheng Biochemicals Low Molecular Heparin Preparation Product Portfolio
Table 97. Dongcheng Biochemicals Recent Developments
Table 98. Zhaoke Pharmaceutical Company Information
Table 99. Zhaoke Pharmaceutical Business Overview
Table 100. Zhaoke Pharmaceutical Low Molecular Heparin Preparation Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Zhaoke Pharmaceutical Low Molecular Heparin Preparation Product Portfolio
Table 102. Zhaoke Pharmaceutical Recent Developments
Table 103. Global Low Molecular Heparin Preparation Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 104. Global Low Molecular Heparin Preparation Sales by Region (2021-2026) & (W Units)
Table 105. Global Low Molecular Heparin Preparation Sales Market Share by Region (2021-2026)
Table 106. Global Low Molecular Heparin Preparation Sales by Region (2027-2032) & (W Units)
Table 107. Global Low Molecular Heparin Preparation Sales Market Share by Region (2027-2032)
Table 108. Global Low Molecular Heparin Preparation Revenue by Region (2021-2026) & (US$ Million)
Table 109. Global Low Molecular Heparin Preparation Revenue Market Share by Region (2021-2026)
Table 110. Global Low Molecular Heparin Preparation Revenue by Region (2027-2032) & (US$ Million)
Table 111. Global Low Molecular Heparin Preparation Revenue Market Share by Region (2027-2032)
Table 112. North America Low Molecular Heparin Preparation Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 113. North America Low Molecular Heparin Preparation Sales by Country (2021-2026) & (W Units)
Table 114. North America Low Molecular Heparin Preparation Sales by Country (2027-2032) & (W Units)
Table 115. North America Low Molecular Heparin Preparation Revenue by Country (2021-2026) & (US$ Million)
Table 116. North America Low Molecular Heparin Preparation Revenue by Country (2027-2032) & (US$ Million)
Table 117. Europe Low Molecular Heparin Preparation Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 118. Europe Low Molecular Heparin Preparation Sales by Country (2021-2026) & (W Units)
Table 119. Europe Low Molecular Heparin Preparation Sales by Country (2027-2032) & (W Units)
Table 120. Europe Low Molecular Heparin Preparation Revenue by Country (2021-2026) & (US$ Million)
Table 121. Europe Low Molecular Heparin Preparation Revenue by Country (2027-2032) & (US$ Million)
Table 122. Asia Pacific Low Molecular Heparin Preparation Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 123. Asia Pacific Low Molecular Heparin Preparation Sales by Country (2021-2026) & (W Units)
Table 124. Asia Pacific Low Molecular Heparin Preparation Sales by Country (2027-2032) & (W Units)
Table 125. Asia Pacific Low Molecular Heparin Preparation Revenue by Country (2021-2026) & (US$ Million)
Table 126. Asia Pacific Low Molecular Heparin Preparation Revenue by Country (2027-2032) & (US$ Million)
Table 127. South America Low Molecular Heparin Preparation Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 128. South America Low Molecular Heparin Preparation Sales by Country (2021-2026) & (W Units)
Table 129. South America Low Molecular Heparin Preparation Sales by Country (2027-2032) & (W Units)
Table 130. South America Low Molecular Heparin Preparation Revenue by Country (2021-2026) & (US$ Million)
Table 131. South America Low Molecular Heparin Preparation Revenue by Country (2027-2032) & (US$ Million)
Table 132. Middle East and Africa Low Molecular Heparin Preparation Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 133. Middle East and Africa Low Molecular Heparin Preparation Sales by Country (2021-2026) & (W Units)
Table 134. Middle East and Africa Low Molecular Heparin Preparation Sales by Country (2027-2032) & (W Units)
Table 135. Middle East and Africa Low Molecular Heparin Preparation Revenue by Country (2021-2026) & (US$ Million)
Table 136. Middle East and Africa Low Molecular Heparin Preparation Revenue by Country (2027-2032) & (US$ Million)
Table 137. Global Low Molecular Heparin Preparation Sales by Type (2021-2026) & (W Units)
Table 138. Global Low Molecular Heparin Preparation Sales by Type (2027-2032) & (W Units)
Table 139. Global Low Molecular Heparin Preparation Sales Market Share by Type (2021-2026)
Table 140. Global Low Molecular Heparin Preparation Sales Market Share by Type (2027-2032)
Table 141. Global Low Molecular Heparin Preparation Revenue by Type (2021-2026) & (US$ Million)
Table 142. Global Low Molecular Heparin Preparation Revenue by Type (2027-2032) & (US$ Million)
Table 143. Global Low Molecular Heparin Preparation Revenue Market Share by Type (2021-2026)
Table 144. Global Low Molecular Heparin Preparation Revenue Market Share by Type (2027-2032)
Table 145. Global Low Molecular Heparin Preparation Price by Type (2021-2026) & (US$/Unit)
Table 146. Global Low Molecular Heparin Preparation Price by Type (2027-2032) & (US$/Unit)
Table 147. Global Low Molecular Heparin Preparation Sales by Application (2021-2026) & (W Units)
Table 148. Global Low Molecular Heparin Preparation Sales by Application (2027-2032) & (W Units)
Table 149. Global Low Molecular Heparin Preparation Sales Market Share by Application (2021-2026)
Table 150. Global Low Molecular Heparin Preparation Sales Market Share by Application (2027-2032)
Table 151. Global Low Molecular Heparin Preparation Revenue by Application (2021-2026) & (US$ Million)
Table 152. Global Low Molecular Heparin Preparation Revenue by Application (2027-2032) & (US$ Million)
Table 153. Global Low Molecular Heparin Preparation Revenue Market Share by Application (2021-2026)
Table 154. Global Low Molecular Heparin Preparation Revenue Market Share by Application (2027-2032)
Table 155. Global Low Molecular Heparin Preparation Price by Application (2021-2026) & (US$/Unit)
Table 156. Global Low Molecular Heparin Preparation Price by Application (2027-2032) & (US$/Unit)
Table 157. Key Raw Materials
Table 158. Raw Materials Key Suppliers
Table 159. Low Molecular Heparin Preparation Distributors List
Table 160. Low Molecular Heparin Preparation Customers List
Table 161. Low Molecular Heparin Preparation Industry Trends
Table 162. Low Molecular Heparin Preparation Industry Drivers
Table 163. Low Molecular Heparin Preparation Industry Restraints
Table 164. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Low Molecular Heparin Preparation Product Image
Figure 5. Global Low Molecular Heparin Preparation Revenue (US$ Million), 2021 VS 2025 VS 2032
Figure 6. Global Low Molecular Heparin Preparation Market Size (2021-2032) & (US$ Million)
Figure 7. Global Low Molecular Heparin Preparation Sales (2021-2032) & (W Units)
Figure 8. Global Low Molecular Heparin Preparation Average Price (US$/Unit) & (2021-2032)
Figure 9. Dalteparin Sodium Product Image
Figure 10. Nadroparin Calcium Product Image
Figure 11. Enoxaparin Sodium Product Image
Figure 12. Hospital Product Image
Figure 13. Pharmacy Product Image
Figure 14. Global Low Molecular Heparin Preparation Revenue Share by Manufacturers in 2025
Figure 15. Global Manufacturers of Low Molecular Heparin Preparation, Manufacturing Sites & Headquarters
Figure 16. Global Top 5 and 10 Low Molecular Heparin Preparation Players Market Share by Revenue in 2025
Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 18. Global Low Molecular Heparin Preparation Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Figure 19. Global Low Molecular Heparin Preparation Sales by Region in 2025
Figure 20. Global Low Molecular Heparin Preparation Revenue by Region in 2025
Figure 21. North America Low Molecular Heparin Preparation Market Size by Country in 2025
Figure 22. North America Low Molecular Heparin Preparation Sales Market Share by Country (2021-2032)
Figure 23. North America Low Molecular Heparin Preparation Revenue Market Share by Country (2021-2032)
Figure 24. United States Low Molecular Heparin Preparation Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 25. Canada Low Molecular Heparin Preparation Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 26. Europe Low Molecular Heparin Preparation Market Size by Country in 2025
Figure 27. Europe Low Molecular Heparin Preparation Sales Market Share by Country (2021-2032)
Figure 28. Europe Low Molecular Heparin Preparation Revenue Market Share by Country (2021-2032)
Figure 29. Germany Low Molecular Heparin Preparation Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 30. France Low Molecular Heparin Preparation Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 31. U.K. Low Molecular Heparin Preparation Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 32. Italy Low Molecular Heparin Preparation Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 33. Netherlands Low Molecular Heparin Preparation Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 34. Nordic Countries Low Molecular Heparin Preparation Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 35. Asia Pacific Low Molecular Heparin Preparation Market Size by Country in 2025
Figure 36. Asia Pacific Low Molecular Heparin Preparation Sales Market Share by Country (2021-2032)
Figure 37. Asia Pacific Low Molecular Heparin Preparation Revenue Market Share by Country (2021-2032)
Figure 38. China Low Molecular Heparin Preparation Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 39. Japan Low Molecular Heparin Preparation Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 40. South Korea Low Molecular Heparin Preparation Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 41. India Low Molecular Heparin Preparation Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 42. Australia Low Molecular Heparin Preparation Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 43. China Taiwan Low Molecular Heparin Preparation Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 44. Southeast Asia Low Molecular Heparin Preparation Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 45. Southeast Asia Low Molecular Heparin Preparation Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 46. South America Low Molecular Heparin Preparation Market Size by Country in 2025
Figure 47. South America Low Molecular Heparin Preparation Sales Market Share by Country (2021-2032)
Figure 48. South America Low Molecular Heparin Preparation Revenue Market Share by Country (2021-2032)
Figure 49. Mexico Low Molecular Heparin Preparation Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 50. Brazil Low Molecular Heparin Preparation Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 51. Argentina Low Molecular Heparin Preparation Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 52. Middle East and Africa Low Molecular Heparin Preparation Market Size by Country in 2025
Figure 53. Middle East and Africa Low Molecular Heparin Preparation Sales Market Share by Country (2021-2032)
Figure 54. Middle East and Africa Low Molecular Heparin Preparation Revenue Market Share by Country (2021-2032)
Figure 55. Turkey Low Molecular Heparin Preparation Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 56. Saudi Arabia Low Molecular Heparin Preparation Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 57. UAE Low Molecular Heparin Preparation Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 58. Global Low Molecular Heparin Preparation Sales Market Share by Type (2021-2032)
Figure 59. Global Low Molecular Heparin Preparation Revenue Market Share by Type (2021-2032)
Figure 60. Global Low Molecular Heparin Preparation Price (US$/Unit) by Type (2021-2032)
Figure 61. Global Low Molecular Heparin Preparation Sales Market Share by Application (2021-2032)
Figure 62. Global Low Molecular Heparin Preparation Revenue Market Share by Application (2021-2032)
Figure 63. Global Low Molecular Heparin Preparation Price (US$/Unit) by Application (2021-2032)
Figure 64. Low Molecular Heparin Preparation Value Chain
Figure 65. Low Molecular Heparin Preparation Production Mode & Process
Figure 66. Direct Comparison with Distribution Share
Figure 67. Distributors Profiles
Figure 68. Low Molecular Heparin Preparation Industry Opportunities and Challenges
Scope & coverage.
Types
- Dalteparin Sodium
- Nadroparin Calcium
- Enoxaparin Sodium
Applications
- Hospital
- Pharmacy
Companies covered
- ALFA WASSERMANN
- Aspen (N.V.Organon)
- Qianhong Bio-pharma
- Tiandong
- GlaxoSmithKline
- Hangzhou Jiuyuan Gene Engineering
- Changshan Pharm
- Pfizer
- Jiangsu Da Lian Pharmaceutical
- King-friend Biochemical Pharmaceutical
- Xinbai
- Qilu Pharmaceutica
- Sanofi
- Hepalink
- Tianjin Chase Sun Pharmaceutical
- Dongcheng Biochemicals
- Zhaoke Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Low Molecular Heparin Preparation Market Size (2021-2032)
- 2.2.2 Global Low Molecular Heparin Preparation Sales (2021-2032)
- 2.2.3 Global Low Molecular Heparin Preparation Market Average Price (2021-2032)
- 2.3 Low Molecular Heparin Preparation by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Dalteparin Sodium
- 2.3.3 Nadroparin Calcium
- 2.3.4 Enoxaparin Sodium
- 2.4 Low Molecular Heparin Preparation by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Pharmacy
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Low Molecular Heparin Preparation Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Low Molecular Heparin Preparation Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Low Molecular Heparin Preparation Revenue of Manufacturers (2021-2026)
- 3.4 Global Low Molecular Heparin Preparation Average Price by Manufacturers (2021-2026)
- 3.5 Global Low Molecular Heparin Preparation Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Low Molecular Heparin Preparation, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Low Molecular Heparin Preparation, Product Type & Application
- 3.8 Global Manufacturers of Low Molecular Heparin Preparation, Established Date
- 3.9 Global Low Molecular Heparin Preparation Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 ALFA WASSERMANN
- 4.1.1 ALFA WASSERMANN Company Information
- 4.1.2 ALFA WASSERMANN Business Overview
- 4.1.3 ALFA WASSERMANN Low Molecular Heparin Preparation Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 ALFA WASSERMANN Low Molecular Heparin Preparation Product Portfolio
- 4.1.5 ALFA WASSERMANN Recent Developments
- 4.2 Aspen (N.V.Organon)
- 4.2.1 Aspen (N.V.Organon) Company Information
- 4.2.2 Aspen (N.V.Organon) Business Overview
- 4.2.3 Aspen (N.V.Organon) Low Molecular Heparin Preparation Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Aspen (N.V.Organon) Low Molecular Heparin Preparation Product Portfolio
- 4.2.5 Aspen (N.V.Organon) Recent Developments
- 4.3 Qianhong Bio-pharma
- 4.3.1 Qianhong Bio-pharma Company Information
- 4.3.2 Qianhong Bio-pharma Business Overview
- 4.3.3 Qianhong Bio-pharma Low Molecular Heparin Preparation Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Qianhong Bio-pharma Low Molecular Heparin Preparation Product Portfolio
- 4.3.5 Qianhong Bio-pharma Recent Developments
- 4.4 Tiandong
- 4.4.1 Tiandong Company Information
- 4.4.2 Tiandong Business Overview
- 4.4.3 Tiandong Low Molecular Heparin Preparation Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Tiandong Low Molecular Heparin Preparation Product Portfolio
- 4.4.5 Tiandong Recent Developments
- 4.5 GlaxoSmithKline
- 4.5.1 GlaxoSmithKline Company Information
- 4.5.2 GlaxoSmithKline Business Overview
- 4.5.3 GlaxoSmithKline Low Molecular Heparin Preparation Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 GlaxoSmithKline Low Molecular Heparin Preparation Product Portfolio
- 4.5.5 GlaxoSmithKline Recent Developments
- 4.6 Hangzhou Jiuyuan Gene Engineering
- 4.6.1 Hangzhou Jiuyuan Gene Engineering Company Information
- 4.6.2 Hangzhou Jiuyuan Gene Engineering Business Overview
- 4.6.3 Hangzhou Jiuyuan Gene Engineering Low Molecular Heparin Preparation Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Hangzhou Jiuyuan Gene Engineering Low Molecular Heparin Preparation Product Portfolio
- 4.6.5 Hangzhou Jiuyuan Gene Engineering Recent Developments
- 4.7 Changshan Pharm
- 4.7.1 Changshan Pharm Company Information
- 4.7.2 Changshan Pharm Business Overview
- 4.7.3 Changshan Pharm Low Molecular Heparin Preparation Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Changshan Pharm Low Molecular Heparin Preparation Product Portfolio
- 4.7.5 Changshan Pharm Recent Developments
- 4.8 Pfizer
- 4.8.1 Pfizer Company Information
- 4.8.2 Pfizer Business Overview
- 4.8.3 Pfizer Low Molecular Heparin Preparation Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Pfizer Low Molecular Heparin Preparation Product Portfolio
- 4.8.5 Pfizer Recent Developments
- 4.9 Jiangsu Da Lian Pharmaceutical
- 4.9.1 Jiangsu Da Lian Pharmaceutical Company Information
- 4.9.2 Jiangsu Da Lian Pharmaceutical Business Overview
- 4.9.3 Jiangsu Da Lian Pharmaceutical Low Molecular Heparin Preparation Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Jiangsu Da Lian Pharmaceutical Low Molecular Heparin Preparation Product Portfolio
- 4.9.5 Jiangsu Da Lian Pharmaceutical Recent Developments
- 4.10 King-friend Biochemical Pharmaceutical
- 4.10.1 King-friend Biochemical Pharmaceutical Company Information
- 4.10.2 King-friend Biochemical Pharmaceutical Business Overview
- 4.10.3 King-friend Biochemical Pharmaceutical Low Molecular Heparin Preparation Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 King-friend Biochemical Pharmaceutical Low Molecular Heparin Preparation Product Portfolio
- 4.10.5 King-friend Biochemical Pharmaceutical Recent Developments
- 4.11 Xinbai
- 4.11.1 Xinbai Company Information
- 4.11.2 Xinbai Business Overview
- 4.11.3 Xinbai Low Molecular Heparin Preparation Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Xinbai Low Molecular Heparin Preparation Product Portfolio
- 4.11.5 Xinbai Recent Developments
- 4.12 Qilu Pharmaceutica
- 4.12.1 Qilu Pharmaceutica Company Information
- 4.12.2 Qilu Pharmaceutica Business Overview
- 4.12.3 Qilu Pharmaceutica Low Molecular Heparin Preparation Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Qilu Pharmaceutica Low Molecular Heparin Preparation Product Portfolio
- 4.12.5 Qilu Pharmaceutica Recent Developments
- 4.13 Sanofi
- 4.13.1 Sanofi Company Information
- 4.13.2 Sanofi Business Overview
- 4.13.3 Sanofi Low Molecular Heparin Preparation Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Sanofi Low Molecular Heparin Preparation Product Portfolio
- 4.13.5 Sanofi Recent Developments
- 4.14 Hepalink
- 4.14.1 Hepalink Company Information
- 4.14.2 Hepalink Business Overview
- 4.14.3 Hepalink Low Molecular Heparin Preparation Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Hepalink Low Molecular Heparin Preparation Product Portfolio
- 4.14.5 Hepalink Recent Developments
- 4.15 Tianjin Chase Sun Pharmaceutical
- 4.15.1 Tianjin Chase Sun Pharmaceutical Company Information
- 4.15.2 Tianjin Chase Sun Pharmaceutical Business Overview
- 4.15.3 Tianjin Chase Sun Pharmaceutical Low Molecular Heparin Preparation Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Tianjin Chase Sun Pharmaceutical Low Molecular Heparin Preparation Product Portfolio
- 4.15.5 Tianjin Chase Sun Pharmaceutical Recent Developments
- 4.16 Dongcheng Biochemicals
- 4.16.1 Dongcheng Biochemicals Company Information
- 4.16.2 Dongcheng Biochemicals Business Overview
- 4.16.3 Dongcheng Biochemicals Low Molecular Heparin Preparation Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Dongcheng Biochemicals Low Molecular Heparin Preparation Product Portfolio
- 4.16.5 Dongcheng Biochemicals Recent Developments
- 4.17 Zhaoke Pharmaceutical
- 4.17.1 Zhaoke Pharmaceutical Company Information
- 4.17.2 Zhaoke Pharmaceutical Business Overview
- 4.17.3 Zhaoke Pharmaceutical Low Molecular Heparin Preparation Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Zhaoke Pharmaceutical Low Molecular Heparin Preparation Product Portfolio
- 4.17.5 Zhaoke Pharmaceutical Recent Developments
5 Global Low Molecular Heparin Preparation Market Scenario by Region
- 5.1 Global Low Molecular Heparin Preparation Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Low Molecular Heparin Preparation Sales by Region: 2021-2032
- 5.2.1 Global Low Molecular Heparin Preparation Sales by Region: 2021-2026
- 5.2.2 Global Low Molecular Heparin Preparation Sales by Region: 2027-2032
- 5.3 Global Low Molecular Heparin Preparation Revenue by Region: 2021-2032
- 5.3.1 Global Low Molecular Heparin Preparation Revenue by Region: 2021-2026
- 5.3.2 Global Low Molecular Heparin Preparation Revenue by Region: 2027-2032
- 5.4 North America Low Molecular Heparin Preparation Market Facts & Figures by Country
- 5.4.1 North America Low Molecular Heparin Preparation Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Low Molecular Heparin Preparation Sales by Country (2021-2032)
- 5.4.3 North America Low Molecular Heparin Preparation Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Low Molecular Heparin Preparation Market Facts & Figures by Country
- 5.5.1 Europe Low Molecular Heparin Preparation Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Low Molecular Heparin Preparation Sales by Country (2021-2032)
- 5.5.3 Europe Low Molecular Heparin Preparation Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Low Molecular Heparin Preparation Market Facts & Figures by Country
- 5.6.1 Asia Pacific Low Molecular Heparin Preparation Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Low Molecular Heparin Preparation Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Low Molecular Heparin Preparation Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Low Molecular Heparin Preparation Market Facts & Figures by Country
- 5.7.1 South America Low Molecular Heparin Preparation Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Low Molecular Heparin Preparation Sales by Country (2021-2032)
- 5.7.3 South America Low Molecular Heparin Preparation Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Low Molecular Heparin Preparation Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Low Molecular Heparin Preparation Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Low Molecular Heparin Preparation Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Low Molecular Heparin Preparation Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Low Molecular Heparin Preparation Sales by Type (2021-2032)
- 6.1.1 Global Low Molecular Heparin Preparation Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Low Molecular Heparin Preparation Sales Market Share by Type (2021-2032)
- 6.2 Global Low Molecular Heparin Preparation Revenue by Type (2021-2032)
- 6.2.1 Global Low Molecular Heparin Preparation Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Low Molecular Heparin Preparation Revenue Market Share by Type (2021-2032)
- 6.3 Global Low Molecular Heparin Preparation Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Low Molecular Heparin Preparation Sales by Application (2021-2032)
- 7.1.1 Global Low Molecular Heparin Preparation Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Low Molecular Heparin Preparation Sales Market Share by Application (2021-2032)
- 7.2 Global Low Molecular Heparin Preparation Revenue by Application (2021-2032)
- 7.2.1 Global Low Molecular Heparin Preparation Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Low Molecular Heparin Preparation Revenue Market Share by Application (2021-2032)
- 7.3 Global Low Molecular Heparin Preparation Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Low Molecular Heparin Preparation Value Chain Analysis
- 8.1.1 Low Molecular Heparin Preparation Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Low Molecular Heparin Preparation Production Mode & Process
- 8.2 Low Molecular Heparin Preparation Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Low Molecular Heparin Preparation Distributors
- 8.2.3 Low Molecular Heparin Preparation Customers
9 Global Low Molecular Heparin Preparation Analyzing Market Dynamics
- 9.1 Low Molecular Heparin Preparation Industry Trends
- 9.2 Low Molecular Heparin Preparation Industry Drivers
- 9.3 Low Molecular Heparin Preparation Industry Opportunities and Challenges
- 9.4 Low Molecular Heparin Preparation Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$2,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst